RecruitingPhase 1Phase 2NCT07263594

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors

Sponsor

DualityBio Inc.

Enrollment

127 participants

Start Date

Jan 20, 2026

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Cancer

Summary

This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DB-1324 for people with gastrointestinal cancer. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDB-1324

Administered I.V.

Locations(9)

USA05-0

Port Saint Lucie, Florida, United States

USA02-0

Grand Rapids, Michigan, United States

USA01-0

Huntersville, North Carolina, United States

USA03-0

Cincinnati, Ohio, United States

AUS02-0

Randwick, New South Wales, Australia

AUS03-0

South Brisbane, Queensland, Australia

AUS01-0

Nedlands, Western Australia, Australia

CHN01-0

Beijing, China

CHN04-0

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07263594

Related Trials

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT0659669462 locations

Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center

NCT064202061 location

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

NCT048470631 location

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

NCT013134421 location

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

NCT070567771 location